Honestly you must ask yourself, is the glass 1/2 empty or 1/2 full???
If "half empty" then Affy stays at $1.00 to $2.00 for 12-24 months until new studies can be completed to appease the FDA. If "half full" then the FDA gives Affy a clear path to end the recall via a warning label and Omontys goes back on the Market and short term we go to $5.00 to $10.00.
Or is the glass broken. It certainly has a hole in the bottom since bankruptcy is threatened and all cash is draining fast. No revenue. No product. Probably half a dozen or fewer employees. Continuing expenses. Crushing litigation. Only asset is "blue sky" Takeda promise to pay milestone/royalties IF Omontys reintroduced to market. No unmet medical need served by Omontys where Epogen/Aranesp, with proven safety profiles are industry standard. PEARL studies and actual patient usage prove Omontys unsafe. I'd say the glass is draining pretty fast to empty.